Characteristic | Patients < 65 years | Patients > 65 years | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | Univariate analysis | Multivariable analysis |  | Univariate analysis | Multivariable analysis | ||||||||
 | N | HR | 95% CI | P | HR | 95% CI | P | N | HR | 95% CI | P | HR | 95% CI | P |
Age | Â | Â | Â | .74 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
< 40 | 33 | 1 | Â | Â | Â | Â | Â | 0 | Â | Â | Â | Â | Â | Â |
40-50 | 98 | 1.10 | 0.62-1.96 | Â | Â | Â | Â | 0 | Â | Â | Â | Â | Â | Â |
50-60 | 101 | 1.29 | 0.73-2.29 | Â | Â | Â | Â | 0 | Â | Â | Â | Â | Â | Â |
> 60 | 44 | 1.29 | 0.66-2.52 | Â | Â | Â | Â | 154 | Â | Â | Â | Â | Â | Â |
Grade | Â | Â | Â | .03 | Â | Â | 0.21 | Â | Â | Â | .01 | Â | Â | .29 |
I | 31 | 1 | Â | Â | 1 | Â | Â | 24 | 1 | Â | Â | 1 | Â | Â |
II | 131 | 1.45 | 0.76-2.75 | Â | 1.06 | 0.40-2.78 | Â | 74 | 1.73 | 0.66-4.58 | Â | 1.30 | 0.48-3.58 | Â |
III | 75 | 2.17 | 1.12-4.20 | Â | 1.54 | 0.58-4.11 | Â | 44 | 3.66 | 1.39-9.61 | Â | 2.01 | 0.70-5.75 | Â |
Histological type | Â | Â | Â | .54 | Â | Â | Â | Â | Â | Â | .53 | Â | Â | Â |
Ductal | 223 | 1 | Â | Â | Â | Â | Â | 124 | 1 | Â | Â | Â | Â | Â |
Other | 15 | 1.24 | 0.63-2.45 | Â | Â | Â | Â | 18 | 0.74 | 0.30-1.87 | Â | Â | Â | Â |
Tumor stage | Â | Â | Â | < .001 | Â | Â | 0.05 | Â | Â | Â | .03 | Â | Â | .90 |
pT1 | 137 | 1 | Â | Â | 1 | Â | Â | 59 | 1 | Â | Â | 1 | Â | Â |
pT2 | 109 | 1.66 | 1.16-2.37 | Â | 1.60 | 1.01-2.55 | Â | 71 | 2.23 | 1.22-4.09 | Â | 1.16 | 0.56-2.40 | Â |
pT3/4 | 22 | 2.73 | 1.57-4.76 | Â | 2.04 | 1.07-3.88 | Â | 18 | 2.11 | 0.82-5.45 | Â | 1.23 | 0.42-3.63 | Â |
Nodal stage | Â | Â | Â | < .001 | Â | Â | < 0.001 | Â | Â | Â | < .001 | Â | Â | < .001 |
Negative | 204 | 1 | Â | Â | 1 | Â | Â | 109 | 1 | Â | Â | 1 | Â | Â |
Positive | 69 | 4.25 | 3.02-5.99 | Â | 4.44 | 2.89-6.82 | Â | 36 | 3.94 | 2.28-6.82 | Â | 3.33 | 1.77-6.24 | Â |
ER status | Â | Â | Â | .59 | Â | Â | Â | Â | Â | Â | .22 | Â | Â | Â |
Negative | 87 | 1 | Â | Â | Â | Â | Â | 40 | 1 | Â | Â | Â | Â | Â |
Positive | 126 | 0.90 | 0.66-1.32 | Â | Â | Â | Â | 95 | 1.53 | 0.78-2.98 | Â | Â | Â | Â |
PgR status | Â | Â | Â | .78 | Â | Â | Â | Â | Â | Â | .78 | Â | Â | Â |
Negative | 84 | 1 | Â | Â | Â | Â | Â | 55 | 1 | Â | Â | Â | Â | Â |
Positive | 123 | 0.95 | 0.64-1.40 | Â | Â | Â | Â | 81 | 1.08 | 0.61-1.92 | Â | Â | Â | Â |
HER2 status | Â | Â | Â | .26 | Â | Â | Â | Â | Â | Â | .05 | Â | Â | Â |
Negative | 143 | 1 | Â | Â | Â | Â | Â | 105 | 1 | Â | Â | Â | Â | Â |
Positive | 19 | 1.44 | 0.76-2.71 | Â | Â | Â | Â | 4 | 0.05 | 0.00-23.3 | Â | Â | Â | Â |
ALDH1 status | Â | Â | Â | .01 | Â | Â | 0.02 | Â | Â | Â | .14 | Â | Â | Â |
Negative | 77 | 1 | Â | Â | 1 | Â | Â | 63 | 1 | Â | Â | Â | Â | Â |
Positive | 116 | 1.75 | 1.14-2.68 | Â | 1.71 | 1.09-2.68 | Â | 61 | 0.64 | 0.35-1.16 | Â | Â | Â | Â |